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Doctors at London’s Great
Ormond Street Hospital
announced earlier this month the
UK’s first apparent success in
using gene therapy to treat a
patient. An 18-month-old boy with
sex-linked severe combined
immune deficiency (SCID) who
was confined to sterile living
conditions now shows an immune
system that looks normal, the
research team announced. It is
only the second case of gene
therapy reaching this level of
success worldwide, and provides
a welcome boost to research after
a decade of often disappointing
and sometimes disastrous results.
Although the patient, Rhys
Evans, shows every sign of being
normal, there is still a risk he may
relapse, making him once again
vulnerable to the opportunistic
infections that strike someone with
a compromised immune system.
Alan Thrasher, the consultant
paediatric immunologist at the
Great Ormond Street Hospital,
who carried out the treatment
said: “Rhys will be followed up for
years and years. Only in the long
term will we really be able to
compare what we’ve done to Rhys
with our other patients who’ve
been through more conventional
transplant procedures.”
For the past 20 years the only
treatment for such patients has
been a bone marrow transplant. So
Rhys was transferred from his local
hospital in in South Wales to a
sterile room at Great Ormond
Street, one of the country’s leading
children’s hospitals. Doctors soon
began the search for a bone
marrow donor, as Rhys did not
have a brother or sister to act as a
tissue-matched donor. “We were
told one day there wasn’t a match
in the UK, and so looked
worldwide,” says Mrs Evans. “A
potential American donor was
found but the next day next day we
were given the opportunity for
gene therapy,” she said.
Bone marrow cells were
extracted from the boy’s hip and
mixed in the lab with a mouse
retrovirus vector containing a
normal version of the boy’s
defective gene. The cells were
then later transfused back into the
patient.
Thrasher said that after the
treatment, Rhys now appears to
have a normal immune system.
“We were enormously relieved.
We were ecstatic. We’ve been
working on gene therapy for many
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New results for gene therapy announced in London this month build on
the success of treatments carried out in Paris reported two years ago.
Together they may provide a vital boost to research in the field which
has flagged in recent years with many disappointing trials carried out.
Nigel Williams reports.
Enthusiastic: Media reports hailed the announcement of gene
therapy success in London this month, as London’s Guardian
shows here, with major coverage of the story. Researchers hope
the gene therapy success and public enthusiasm will help
bolster new research programmes in a field which has been in
the doldrums over recent years.
years in the laboratory and it’s
great to be able to take that work
into the clinic and see some
therapeutic success.” A second
10-month-old child with SCID also
underwent gene therapy at Great
Ormond Street four months ago.
The patient is doing even better
than Rhys at a comparable stage,
the team said.
Thrasher said that Great Ormond
Street had applied to the Gene
Therapy Advisory Committee
(GTAC) for permission to conduct
further trials on other conditions.
“In principle, it means we can
extend this type of therapy to other
blood diseases and that’s going to
be hugely important for many of
our patients who don’t have bone
marrow donors.” The first patient
to receive gene therapy, Ashanti
De Silva, was treated by a team at
the US National Institutes of Health
in 1990. She is still doing well
today but this is thought more
likely to be the result of the drugs
she takes than the success of the
gene therapy.
The reality is that it has been a
struggle to get gene therapy to
work. “There was initially a great
burst of enthusiasm that lasted
three, four years, where a couple
of hundred of trials got started all
over the world,” says gene
therapy pioneer W. French
Anderson who led the NIH team
that treated Ashanthi. “Then we
realised that nothing was really
working at a clinical level.”
And that was before tragedy in
September 1999, when a young
American called Jesse Gelsinger
died after a gene therapy injection
into his liver. It seems his immune
system launched a major attack on
the adenovirus vector. After that,
he suffered an overwhelming
series of organ failures. Questions
were raised not just about whether
gene therapy would ever work, but
whether it would ever be safe.
Over the past two years
however, gene therapy has begun
to experience a renaissance. In
April 2000, a team of French
scientists, led by Alain Fischer at
the Necker Hospital in Paris,
published research showing
unequivocally for the first time
that gene therapy could correct
SCID disease in young children.
The team used a slightly different
virus vector to that exploited by
the London team. Four months
after that announcement, US
doctors said they had halted the
growth of head and neck tumours
using a form of gene therapy.
There is also great interest in
trials on haemophilia patients. It is
another sex-linked disorder which
causes failure to produce vital
blood clotting factors. The
condition can affect one in every
5,000 boys. Katherine High, a
haematologist at the Children’s
Hospital in Philadelphia and Mark
Kay, a geneticist at Stanford
University, are studying
haemophilia B, the less common
form of the disease.
We were enormously
relieved. We were ecstatic.
We’ve been working on
gene therapy for many
years in the laboratory and
it’s great to be able to take
that work into the clinic
and see some therapeutic
success
One of the attractions of
haemophilia for gene therapy is
that a patient only needs to
produce very low levels of the
missing factor compared with
normal levels to restore patients to
a much more manageable disease.
The team hope to get patients to
produce just one per cent of the
normal level of clotting factor which
would be sufficient to prevent most
of the joint damage and bleeding
complications of the disease.
But haemophilia’s attraction for
therapy also has a downside.
Because it can be treated quite
effectively, if inconveniently, with
injection of factors, gene therapy
experiments raise ethical issues.
However, the team got the go
ahead and initial results with three
patients injected into thigh
muscles with a viral vector
containing the gene for the
defective clotting factor, proved
successful. Within two to three
months two patients were
producing a sufficient amount of
the factor to reduce the number of
injections of the clotting factor
they needed. But most
importantly, none of the patients
showed any side effects. 
One key aspect of the trial was
the type of vector used to carry
the gene into the patient’s cells.
Instead of using adenovirus,
which was implicated in
Gelsinger’s death, the scientists
used adeno-associated virus
(AAV). Unlike adenovirus, AAV
does not appear to stimulate the
human immune system.
As more patients were recruited
into the trial, the next phase was
planned — direct injection into the
patient’s liver. It is hoped this will
result in a significant boost in
factor levels. However this part of
the trial came to a halt late last
year when virus was discovered in
the semen of some of the patients.
This raised one of the biggest
worries for some about gene
therapy: the potential to alter
germ line cells. This presents an
overriding concern for the
regulatory bodies. Norman Nevin,
the chairman of GTAC, said that
one of the guiding principles on
which his committee makes
decisions is that there is little or
no risk of altering the genes of
sperm or eggs.
But further work by the US team
found that the viral genes had not
entered sperm cells and the virus
was eventually cleared from the
semen. The US Food and Drug
Administration gave the go ahead
for the trial to continue earlier this
year. And the US agencies are also
insisting High and Kay’s trial makes
regular and detailed analyses to
ensure germline alterations are not
occurring unwittingly.
Others are now hoping to follow
the US lead and also begin trials
on haemophilia and other genetic
diseases. Haematologist Christine
Lee at the Royal Free Hospital in
London hopes trials in the UK will
be under way within five years. 
Studies on new vectors and
new routes for the transfer of
genes are likely to gain from these
latest clinical results. There is no
doubt such a dramatic
transformation in a patients’
condition, in the face of otherwise
devastating genetic diseases, will
bolster new enthusiasm for
research. 
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